Vol. 23/No. 23 | Oncology Live®

PI3K Inhibitors Face Challenges in Hematologic Malignancies

December 02, 2022

Pathways

The PI3K cell-signaling network has been an important therapeutic target in oncology research for nearly 40 years ago, but the use of PI3K inhibitors in hematologic malignancies has come under scrutiny amid concerns about efficacy and safety.

BRONx-CAN Program Aims to Deliver the Best Cancer Treatments Early

December 01, 2022

Partner Perspective

Montefiore Einstein Cancer Center hopes to begin combating systemic inequities and improve cancer outcomes for historically disadvantaged populations by taking a data-driven approach to delivering neoadjuvant therapy in communities that are economically and socially marginalized.

Effective Communication on HPV Vaccination Benefits Is Needed

November 29, 2022

Several articles in a recent issue of the high-impact journal Science highlight areas of concern in the scientific community that may have detrimental effects on communications regarding the human papillomavirus vaccination as a cancer prevention strategy.